With revised IPO pitch, Artiva touts ‘natural killer’ cell therapy for autoimmune disease
细胞疗法IPO免疫疗法临床2期
Dive Brief:
Two years after canceling an initial public offering, Artiva Biotherapeutics has filed a new proposal centered around plans to develop a donor-derived cell therapy for autoimmune disease.
The company originally registered for an IPO in April 2021 to support studies of a blood cancer treatment derived from “natural killer,” or NK cells. Eighteen months later, though, Artiva pulled the deal and instead formed a partnership with German biotechnology company Affimed to co-develop the therapy.
Artiva’s alliance with Affimed is ongoing. But a new IPO pitch revealed Friday includes a focus on autoimmune diseases, where Artiva claims to have been the first company cleared by U.S. regulators to bring a donor-derived, NK cell therapy to human testing. An early-stage study in lupus, as well as a “basket” trial in multiple inflammatory conditions, are ongoing. Initial results from the latter study are expected next year.
Dive Insight:
Like many of its cell therapy peers, Artiva reshuffled its strategy hoping to ride a recent wave of investor interest in autoimmune disease research.
The company is one of a number of biotechs to emerge in recent years to develop so-called allogeneic or “off-the-shelf” cell therapies, which are thought of as convenient, easier-to-manufacture alternatives to the personalized CAR-T treatments used on a handful of blood cancers. Unlike those therapies, Artiva’s are harvested from donor cells. They’re also made from NK cells, which have different characteristics than the immune cells involved in CAR-T therapy.
Such companies have struggled to stand out in cancer, though. Promising early results largely haven’t translated to the long-lasting remissions associated with CAR-T therapies. Personalized therapies have also proven themselves in earlier treatment settings, raising the bar for allogeneic cell therapy makers. Multiple publicly traded developers, like Allogene Therapeutics, Fate Therapeutics and Nkarta, have lost most of their market value and responded by changing course.
Those rearranged plans have often involved a foray into autoimmune disease. Cell therapies aren’t available for inflammatory conditions like lupus, but academic research has suggested they might have powerful, durable effects. About a dozen clinical trials have begun, and many more are on the way. Early data have shown potential, but also room for improvement.
A majority of those trials are testing personalized CAR-T treatments. Allogeneic developers are following closely behind, and contend the potential advantages of donor-derived therapies — like cheaper production costs and lower side effect rates — could be more important in autoimmune disease. In its IPO filing, Artiva pointed to possible edges in safety, scalability and cost.
Artiva also said in that filing that the early clinical results it accrued in cancer “provide a readthrough to autoimmune disease.” But it doesn’t yet have human data to back up those claims. In April, Artiva dosed its first patient in a study evaluating a combination of one of its treatments with a pair of antibody drugs in lupus nephritis. A second study is also underway enrolling people with a variety of conditions, such as rheumatoid arthritis and pemphigus vulgaris.
The lupus study has a primary completion date of 2026, according to a federal database.
'
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。